Skip to main content
HR 2917 116th Congress House Health Child health Civil actions and liability Consumer affairs Corporate finance and management Criminal procedure and sentencing Drug safety, medical device, and laboratory regulation Drug trafficking and controlled substances Drug, alcohol, tobacco use Government studies and investigations Government trust funds Health care coverage and access Health programs administration and funding Marketing and advertising Prescription drugs Securities Wages and earnings

Opioid Crisis Accountability Act of 2019

Introduced: May 22, 2019 See on congress.gov
Sign in to write a letter Sign in to watch
 Everywhere this bill has been 3 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
May 23, 2019
Referred to the Subcommittee on Health.
May 22, 2019
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Education and Labor, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
May 22, 2019
Introduced in House
 Plain-English summary Congressional Research Service

Opioid Crisis Accountability Act of 2019

This bill establishes a series of restrictions and requirements relating to opioid marketing and distribution practices.

Specifically, the bill prohibits (1) knowingly making false advertising or marketing claims regarding the addictive nature of opioids; (2) knowingly supplying communities with quantities of opioids that are not medically reasonable; or (3) failing to report distribution orders, or patterns of orders, while knowing that the orders are not being dispensed in a medically reasonable manner. Employees of opioid manufacturers and distributors are subject to civil penalties and imprisonment for violations; corporations and executives are subject to civil penalties. Manufacturers shall also lose their period of market exclusivity.

Additionally, the Department of Health and Human Services must assess a fee against each corporation that, between January 1, 1993, and the date of enactment of this bill, manufactured or distributed opioids, if such opioids were covered under a federal health program at least once during this period. Manufacturers that fail to pay the fee shall lose associated drug approval until the fee is paid in full.

The bill authorizes collected civil penalties and fees to be used for activities that address opioid misuse and abuse, including family and educational programs.

What's happening now May 23, 2019

Referred to the Subcommittee on Health.

 Committees of jurisdiction 3
 Cosponsors 1
All 1 Democratic 1